 MONT-SAINT-GUIBERT, Belgium, March 01, 2021 GLOBE NEWSWIRE -- Mont-Saint-Guibert, Belgium Celyad Oncology SA Euronext Nasdaq: CYAD, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell CAR T therapies for cancer, today announced that the company plans to participate at the following virtual investor conferences in March 2021: 